Clinical TopicsDermatologyNews

Potential new treatment for atopic dermatitis

Share
By: Lydia L. Kim, Digital Content Editor

Eczema is a common ailment for many people, but a more severe type of eczema not as well-known, atopic dermatitis (AD), may have a new treatment option available.

AD is a more severe manifestation of eczema symptoms, and based on my previous research into the patient and caregiver community, there is a need for more awareness on their diagnosis.

A recent study from the American Association for the Advancement of Science recently released data from a phase 2 clinical trial of etokimab’s efficacy to treat AD. According to AnaptysBio, etokimab ““inhibits the activity of IL-33, a pro-inflammatory cytokine,” which can help modulate skin inflammation.

Please read more about the study here, and more about etokimab here.

Sources:
https://stm.sciencemag.org/content/11/515/eaax2945
https://www.anaptysbio.com/pipeline/etokimab/

*Online Bonus Content: This has not been peer reviewed. The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal.

1 Comment.

  • This looks like an intriguing study that warrants further research. It would be great if it can be established that this type of inhibitory activity can be connected to reduced dermatitis outbreaks.

Comments are closed.

Take the 2024 Nursing Trends and Salary Survey, available now through November 1st 2024

See Past Results
cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

What is the primary purpose of a 3-minute foot assessment in patients with comorbidities such as diabetes or peripheral arterial disease?

More News